HIỆU QUẢ ĐIỀU TRỊ CỦA LIỆU PHÁP BEVACIZUMAB KẾT HỢP HÓA CHẤT TRONG UNG THƯ BIỂU MÔ BUỒNG TRỨNG TÁI PHÁT NHẠY PLATINUM

Abstract

Objective: To evaluate the survival effect of bevacizumab combined with chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. Research methods: Retrospective descriptive study with longitudinal follow-up. Enrolling platinum-sensitive recurrent ovarian cancer patients at K Hospital for 5 years from 2018-2023, who have never received systemic treatment for recurrent disease. Data on patient characteristics, clinical and paraclinical information, treatment characteristics and treatment results were collected through medical records. Data on survival was collected directly from patients and families. Progression-free survival was estimated using the Kaplan Meier method. Results: There were 68 patients eligible included in the analysis. The median age of the patient group was 54 years old, 80% of patients had high-grade serous histology, the proportion of patients with increased CA125 at the time of recurrence was 73%. Threre was 41,2% of patients receive surgery to treat recurrent disease. All patients received first-line treatment with bevacizumab combined with chemotherapy. The response rate was 47%. At follow-up of 16.3 months, the median progression-free survival time was 15.2 months. The PFS time was significantly longer in the group with PFI interval over 12 months compared to the group with PFI from 6-12 months. There was no difference in PFS when analyzed by age, CA125 elevation at the time of recurrence, initial disease stage, surgery status for recurrence, and results of surgery for recurrence. Overall survival data are not yet mature enough for analysis. Conclusion: Bevacizumab combined with chemotherapy in Vietnamese patients with platinum-sensitive recurrent ovarian cancer is effective as expected.